Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 4,340	$ 4,678
General and administrative	3,634	2,903
Loss from operations	(7,974)	(7,581)
Other income (expense), net:
Interest expense	(368)	(344)
Interest income and other income (expense), net	438	289
Total other income (expense), net	70	(55)
Provision for income taxes	0	0
Net loss	$ (7,904)	$ (7,636)
Net loss per share of common stock, RSUs and pre-funded warrants, basic	$ (0.36)	$ (0.55)
Net loss per share of common stock, RSUs and pre-funded warrants, diluted	$ (0.36)	$ (0.55)
Weighted-average shares of common stock and pre-funded warrants outstanding, basic	22,234,225	13,763,173
Weighted-average shares of common stock and pre-funded warrants outstanding, diluted	22,234,225	13,763,173